Mirum Pharmaceuticals, Inc.
MIRM
株式のランク
#3243
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
株価
$83.62
最終同期: 2026-10-21
時価総額
$5.43B
変化（1日）
-1.71%
変化（1年）
20.14%
国
US
取引 Mirum Pharmaceuticals, Inc. (MIRM)
カテゴリー
Healthcare
Mirum Pharmaceuticals, Inc.（MIRM）の株価履歴
終値の最高値: $82.31 （2026-10-01）
終値の最安値: $13.66 （2019-07-01）
終値の最安値: $13.66 （2019-07-01）
Mirum Pharmaceuticals, Inc. の株価履歴（2019 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 28.91% |
| 2025 | 68.24% |
| 2024 | 35.06% |
| 2023 | 73.09% |
| 2022 | 24.19% |
| 2021 | -29.47% |
| 2020 | 29.71% |
| 2019 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.00 | 7.59% |
CH
|
